Delving into the Latest Updates on Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs) with Synapse

Overview

Basic Info

Drug Type

Exosomes

Synonyms

XoGlo

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Kimera Labs, Inc.

Active Organization

Kimera Labs, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

A Stratified Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase I/IIa Clinical Trial to Assess the Safety and Efficacy of a Single Intravenous Dose of Isolated, Placental, Mesenchymal Stem Cell-derived Extracellular Vesicles for the Treatment of COVID-19 Symptoms in Adults With Mild to Moderate Illness

Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in adults with mild to moderate illness.

Start Date01 Jan 2027

Sponsor / Collaborator

Kimera Labs, Inc.

ISRCTN33578935

/ RecruitingPhase 2

Rationale and investigational study for the treatment of COVID-19 with severe viral pneumonia with isolated, placental, mesenchymal stem cell exosomes

Start Date01 Jun 2020

Sponsor / Collaborator

Kimera Labs, Inc.

100 Clinical Results associated with Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs)

Login to view more data

100 Translational Medicine associated with Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs)

Login to view more data

100 Patents (Medical) associated with Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs)

Login to view more data

100 Deals associated with Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs)

Login to view more data